Profile_bird

Hey there! BiotechNews is using Twitter.

Twitter is a free service that lets you keep in touch with people through the exchange of quick, frequent answers to one simple question: What's happening? Join today to start receiving BiotechNews's tweets.

Already using Twitter
from your phone? Click here.

BiotechNews

  1. Genzyme recruits star players to calm rattled investors: With new competition breathing down its neck and bad pre... http://bit.ly/68x8Rf about 16 hours ago from twitterfeed
  2. Gilead wins FDA panel vote for CF therapy: It's taken Gilead Sciences longer than it expected, but the developer ha... http://bit.ly/6lElWr about 17 hours ago from twitterfeed
  3. Glaxo inks $173M deal for Intercell's vax patch: Shares of Intercell were fired up by news that GlaxoSmithKline is ... http://bit.ly/5Ed8bn about 17 hours ago from twitterfeed
  4. Genentech sheds pact as pipeline review claims another deal: Roche has shed yet another development partnership dea... http://bit.ly/60EM5w about 18 hours ago from twitterfeed
  5. Lilly's bullish pipeline review can't quell skeptics: Eli Lilly is touting plans to roll out two new medicines a y... http://bit.ly/8YSDAn 9:05 AM Dec 10th from twitterfeed
  6. AstraZeneca outlines pricey licensing strategy: AstraZeneca faces a critical challenge in gaining new approvals ahe... http://bit.ly/7SvjVr 6:38 AM Dec 10th from twitterfeed
  7. Glaxo hands back another cancer drug to Cytokinetics: GlaxoSmithKline is parting ways with Cytokinetics (CYTK) on a... http://bit.ly/7uVqbh 5:27 AM Dec 10th from twitterfeed
  8. Protalix races to FDA with Gaucher's drug app: With Pfizer at its back, Israel's Protalix has pushed ahead with an ... http://bit.ly/8NLo0M 5:27 AM Dec 10th from twitterfeed
  9. Regeneron plots $40M expansion, 400 new hires: New York-based Regeneron is blueprinting plans for a $40 million exp... http://bit.ly/5Qo267 9:03 AM Dec 9th from twitterfeed
  10. Repligen imaging agent fails Phase III primary endpoint: A late-stage trial of Repligen's RG1068--a pancreatic imag... http://bit.ly/4SoGfC 9:03 AM Dec 9th from twitterfeed
  11. Upcoming webinar features clinical trial thought leaders: We're putting the final pieces together for our upcoming ... http://bit.ly/8wFFIl 9:03 AM Dec 9th from twitterfeed
  12. Feds' anthrax shift triggers sharp drop in developers' shares: The U.S. Department of Health and Human Services has... http://bit.ly/8cs7BG 7:48 AM Dec 9th from twitterfeed
  13. Pfizer hunting for partners in biosimilar quest: Faced with the prospect of losing billions of dollars to generic c... http://bit.ly/4LRN6b 6:40 AM Dec 9th from twitterfeed
  14. Epizyme amps up Series B to $40M: Epizyme has lured New Enterprise Associates into its venture capital fold and add... http://bit.ly/8pvxOs 12:32 PM Dec 8th from twitterfeed
  15. Biotech faces the tipping point for personalized meds: One reason the deal-making tempo in biotechnology is speedi... http://bit.ly/8NoxgW 10:29 AM Dec 8th from twitterfeed
  16. ZymoGenetics forges $182M antibody deal with Novo: Antibodies make up one of the hottest markets for new therapeuti... http://bit.ly/5WKERp 10:29 AM Dec 8th from twitterfeed
  17. Roche dumps another partner as it focuses on Genentech: A day after ending a collaboration with Genmab on an antibo... http://bit.ly/7Y5ziC 10:29 AM Dec 8th from twitterfeed
  18. Therasis gains $12M Series A cash: A start-up biotech company with deep scientific roots in New York has garnered $... http://bit.ly/77Ql9b 10:29 AM Dec 8th from twitterfeed
  19. ASH roundup: Ariad, Cephalon and Novartis make a splash: There's plenty of news spilling out of the ASH meeting tod... http://bit.ly/8dJiFV 10:29 AM Dec 8th from twitterfeed
  20. Zogenix pushes its Series B to $71M: San Diego-based Zogenix has piled an additional $20 million on its Series B, b... http://bit.ly/8eWdDx 11:27 AM Dec 7th from twitterfeed